Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/16/2021 06/17/2021 06/18/2021 06/21/2021 06/22/2021 Date
67.33(c) 67.22(c) 66.61(c) 67.35(c) 67.05(c) Last
12 938 705 7 015 715 11 464 711 5 310 613 4 796 795 Volume
-1.12% -0.16% -0.91% +1.11% -0.45% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 24 680 M - -
Net income 2021 6 885 M - -
Net Debt 2021 21 984 M - -
P/E ratio 2021 12,7x
Yield 2021 4,19%
Sales 2022 23 833 M - -
Net income 2022 7 010 M - -
Net Debt 2022 17 208 M - -
P/E ratio 2022 12,3x
Yield 2022 4,40%
Capitalization 84 093 M 84 093 M -
EV / Sales 2021 4,30x
EV / Sales 2022 4,25x
Nbr of Employees 13 600
Free-Float 99,9%
More Financials
Company
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular... 
More about the company
Ratings of Gilead Sciences, Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about GILEAD SCIENCES, INC.
06/22SHANGHAI FOSUN PHARMACEUTICALá : Fosun Pharma Wins Nod to Market Lymphoma Drug i..
MT
06/22SHANGHAI FOSUN PHARMACEUTICALá : Chinese regulator approves first CAR-T cell the..
RE
06/22GILEAD SCIENCESá : to Present More Than 70 Abstracts From Diverse Liver Disease ..
AQ
06/22GILEAD SCIENCESá : Veklury Associated With a Reduction in Mortality Rate in Hosp..
AQ
06/22Mastercard Foundation Appoints Robin Washington to Board of Directors
DJ
06/21GILEAD SCIENCESá : Says Veklury Lowers Mortality Rate in COVID-19 Treatment
MT
06/21GILEAD SCIENCESá : remdesivir reduces COVID-19 mortality risk- data
RE
06/21GILEAD SCIENCESá : Statement on New England Journal of Medicine Publication of P..
AQ
06/21GILEAD SCIENCESá : Veklury« (Remdesivir) Associated With a Reduction in Mortalit..
BU
06/21GILEAD SCIENCESá : to Present More Than 70 Abstracts From Diverse Liver Disease ..
BU
06/17GILEAD SCIENCESá : Kite Partners With Shoreline Biosciences to Develop Cancer Th..
MT
06/17GILEAD SCIENCESá : Kite and Shoreline Biosciences Enter Into Strategic Partnersh..
BU
06/15UPDATE : Jounce Therapeutics to Get $25 Million From Gilead Sciences After FDA C..
MT
06/15Jounce Therapeutics Shares Rise 13% on IND Clearance for Cancer Treatment
DJ
06/15JOUNCE THERAPEUTICSá : Set for $25 Million Milestone Payment from Gilead After I..
MT
More news
News in other languages on GILEAD SCIENCES, INC.
06/04Galapagos publiceert onderzoeksdata over filgotinib
06/03Covid, accordo Ue per 55.000 dosi trattamento sperimentale Roche-Regeneron
06/02DGAP-NEWS : MorphoSys übernimmt Constellation -2-
06/02DGAP-ADHOC : MorphoSys AG übernimmt Constellation -2-
05/18Galapagos start nieuwe studie naar filgotinib
More news
Analyst Recommendations on GILEAD SCIENCES, INC.
More recommendations
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Last Close Price 67,05 $
Average target price 75,15 $
Spread / Average Target 12,1%
EPS Revisions
Managers and Directors
NameTitle
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.15.09%84 469
WUXI APPTEC CO., LTD.24.70%66 143
REGENERON PHARMACEUTICALS10.54%55 327
BIONTECH SE190.10%54 605
VERTEX PHARMACEUTICALS-20.09%48 589
BEIGENE, LTD.28.69%30 138